FDA cleared the uMI Panvivo (uMI Panvivo LS); uMI Panvivo (uMI Panvivo); uMI Panvivo (uMI Panvivo S); uMI Panvivo (uMI Panvivo EX); uMI Panvivo (uMI Panvivo ES) from Shanghai United Imaging Healthcare Co., Ltd. on Apr 3, 2026 under K260524, a traditional 510(k). The device falls under product code KPS, System, Tomography, Computed, Emission, regulated at 21 CFR 892.1200 as a Class 2 device. The review panel was Radiology.
FDA logged the submission as received on Feb 17, 2026. The decision came 45 days later, inside the 90 FDA-day goal for a 510(k).
Shanghai United Imaging Healthcare Co., Ltd. has 7 other decisions in the tracker over the last 12 months: K253726 (uAngio AVIVA CX), K261427 (uMI Panvivo (uMI Panvivo M)), K260113 (uMR Astra), K253077 (uOmnispace.MR).
Questions & Answers
What did FDA clear under K260524?
K260524 is the FDA 510(k) for uMI Panvivo (uMI Panvivo LS); uMI Panvivo (uMI Panvivo); uMI Panvivo (uMI Panvivo S); uMI Panvivo (uMI Panvivo EX); uMI Panvivo (uMI Panvivo ES), submitted by Shanghai United Imaging Healthcare Co., Ltd.. FDA's decision date was Apr 3, 2026, under product code KPS (System, Tomography, Computed, Emission).
Who makes the uMI Panvivo (uMI Panvivo LS); uMI Panvivo (uMI Panvivo); uMI Panvivo (uMI Panvivo S); uMI Panvivo (uMI Panvivo EX); uMI Panvivo (uMI Panvivo ES)?
Shanghai United Imaging Healthcare Co., Ltd., based in Shanghai, is the applicant of record for K260524.
How long did the K260524 review take?
FDA received the submission on Feb 17, 2026 and issued its decision on Apr 3, 2026, 45 days later.